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ABSTRACT 
Background 
8000 cases of renal cancer are diagnosed each year in the UK, with a five-year survival 
rate of 50%. Treatment options are limited; a potential therapeutic target is the non-
canonical NF-kappa B pathway. This pathway plays a role in multiple oncogenic 
processes in solid tumors. The aim of this study was to investigate the non-canonical 
NF-kappa B pathway in renal cell carcinoma.  
Materials and Methods 
NIK, IKKα and RelB were investigated via immunohistochemistry in a cohort of 192 
patients with clear cell renal cancer.  
Results 
High cytoplasmic NIK was associated with poorer cancer-specific survival (p=0.006) 
and 10-year survival stratified from 85% (low) to 65% (high, p=0.005).  Similarly, high 
cytoplasmic RelB was associated with poorer cancer-specific survival (p=0.041) and 
10-year survival stratified from 88% (low) to 73% (high, p=0.030). When 
clinicopathological characteristics were assessed, cytoplasmic NIK was associated with 
survival (p=0.014). Whereas, cytoplasmic RelB was associated with increased tumor 
grade (p=0.020) and decreased inflammation (p=0.019). Upon multivariate analysis 
cytoplasmic NIK was independently associated with cancer-specific survival 
(p=0.009). 
Conclusions 
The non-canonical NF-kappa B pathway is associated with poorer cancer-specific 
survival in renal cell carcinoma patients, making it a viable target for therapeutic 
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intervention. Furthermore, cytoplasmic NIK is a potential prognostic biomarker for this 
disease. 
 
KEY OF DEFINITIONS FOR ABBREVIATIONS 
CSS = Cancer specific survival 
IRI = Ischemia-reperfusion injury 
NFκB = Nuclear factor kappa B 
RCC = Renal cell carcinoma 
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INTRODUCTION 
Renal cell carcinoma (RCC) is the 8th most common cancer in the UK with a 5-year 
survival rate of around 50%.1 Incidence rates have been rising due to the development 
of modern imaging techniques for earlier cancer detection as well as a rise in risk 
factors such as smoking and obesity.  Chemotherapy is largely ineffective as RCCs 
have high expression levels of the multi-drug resistance protein, P-glycoprotein. 
Commonly used modes of first-line systemic therapy include Sunitinib and Pazopanib 
(tyrosine kinase inhibitor), Bevacizumab (vascular endothelial growth factor inhibitor), 
interferon α (immunotherapy), and Temsirolimus (mammalian target of rapamycin 
inhibitor).2 The ineffectiveness of chemotherapy limits the number of available 
treatment options for patients, thus research into pathways contributing to RCC 
tumorigenesis is necessary to identify drug targets and develop potential therapeutics.  
Nuclear factor kappa B (NFκB) is a family of transcription factors which can act via 
either the canonical or non-canonical pathway. The non-canonical pathway activates 
NIK, which subsequently phosphorylates IKKα. IKKα then phosphorylates p100, 
leading to ubiquitination of p100 and release of active p52:RelB dimers. The p52:RelB 
dimers can then translocate to the nucleus where they drive gene transcription.3, 4 The 
functions of genes transcribed by NFκB can be divided into 4 broad categories, 
immunoregulatory and inflammatory genes, anti-apoptotic genes, genes promoting cell 
proliferation and negative regulators of NFκB, all of which are important in RCC.  It is 
also known that dysregulation of these target genes lead to tumorigenesis in a variety of 
cancers.5  
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The importance of the non-canonical pathway has been demonstrated in various types 
of solid tumors. In breast cancer, the non-canonical pathway can be activated via the 
RANK ligand. Either inhibiting RANK or constitutive RANK activation causes 
elevation of NFκB activity, which subsequently stimulates cell proliferation via 
increased transcription of cyclin D1.5 In glioblastoma this pathway is implicated to 
cause a very aggressive subtype. In mouse xenografts, NIK was shown to cause 
changes in cell conformation, increasing invasive capacity of tumor cells.6 Studies 
looking at the role of the non-canonical pathway in renal cells have also been 
performed, but have not specifically assessed RCC.  In renal cells, Tumor Necrosis 
Factor-like Weak Inducer of Apoptosis (TWEAK) can activate the non-canonical 
NFκB pathway to induce production of inflammatory mediators, as well as induction of 
apoptosis during kidney injury and cell proliferation.7, 8 This pathway has been 
implicated in various renal diseases such as diabetic nephropathy, glomerular disease 
and acute kidney injury but its role in RCC is still unclear.9 
Therefore, this study aimed to investigate the role of the non-canonical NFκB pathway 
in clear cell RCC, using immunohistochemistry to assess protein expression of NIK, 
IKKα and RelB.  Expression was then correlated with patient survival and clinical 
outcome measures. 
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METHODS 
Patient cohorts 
The cohort consist of 192 patients within the Greater Glasgow National Health Service 
(NHS) Trust who were diagnosed with clear cell RCC and underwent complete 
resection of tumor via nephrectomy between 1997 and 2008. Patients were staged and 
graded according to the TMN classification and Fuhrman grading respectively.  Ethical 
approval for use of renal tissue and patient data was obtained from the NHS Greater 
Glasgow & Clyde Biorepository and West of Scotland Research Ethics Service.  
 
Immunohistochemistry 
Immunohistochemical analysis of NIK, IKKα and RelB were carried out using 
previously constructed clear cell RCC tissue microarray (TMA).   
Sections were dewaxed in Histoclear then rehydrated using graded alcohols. Antigen 
retrieval was performed using citrate buffer pH6 under pressure for 5 minutes before 
cooling for 20 minutes. Endogenous peroxidase activity was blocked using 3% 
hydrogen peroxide for 10 minutes. 5% horse serum (Vector Laboratories) for IKKα and 
RelB or 10% Casein for NIK were applied for 30 minutes at room temperature as a 
blocking solution.  Slides were incubated overnight at 4ºC with IKKα (Genway), RelB 
(Cell Signaling Technology) and NIK (abcam) at concentrations of 1:2000, 1:100 and 
1:250, respectively.  Envision (Dako) was added to the sections for 30 minutes at room 
temperature before washing in TBS. DAB substrate was added for five minutes until 
color developed before washing in running water for ten minutes.  Slides were then 
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counterstained in hematoxylin for 60 seconds and blued with Scotts’ tap water before 
being dehydrated through a series of graded alcohols.  Cover slips were applied using 
distrene, plasticizer, xylene (DPX). 
 
Scoring 
Stained TMA sections were scanned using a Hamamatsu NanoZoomer (Welwyn 
Garden City, Hertfordshire, UK) at x20 magnification and visualized on Slidepath 
Digital Image Hub (Leica Biosystems, Milton Keynes, UK). Assessment of NIK, IKKα 
and RelB expression was performed by a single examiner (J.L) blinded to clinical data 
at x20 magnification (total magnification x400) using the weighted histoscore.10  The 
weighted histoscore is calculated as follows: 0x% not stained + 1x% weakly stained + 
2x% moderately stained + 3x% strongly stained.  This gives a range of scores from 0 to 
300 and is calculated individually for nuclear, membrane and cytoplasmic staining. To 
ensure reproducibility, 10% of tumors were co-scored by a co-investigator (J.E.). 
 
Statistical analysis 
Statistical analysis was carried out using SPSS software. For all statistical analyses, the 
p-value was set at <0.05.  Only patients with a score for IKKα, NIK and RelB were 
included in the analysis (n=174). The histoscores for NIK and IKKα where 
dichotomized using the median as the cut-off, whereas RelB was dichotomised using 
the lower quartile as the cut-off.  The relationship between clinicopathological 
characteristics and protein expression was examined using the chi-square test for linear 
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trend.  The relationship between expression and cancer-specific survival was examined 
using the Kaplan-Meier method. The log rank test was utilized to compare significant 
differences between subset groups using univariate analysis. Multivariate cox 
regression analysis was performed to identify those factors that were independently 
associated with cancer specific survival (CSS). 
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RESULTS 
The cohort consisted of 192 RCC patients of which, 135 were alive at the last follow-
up, 36 died of RCC and 20 died of other causes.  Median age of diagnosis is 61 years. 
The length of follow up ranges from 0.1 to 182 months, with a mean follow up time of 
74 months. Mean CSS is 35 months (range 0.1 - 98 months).  
For this cohort a tissue-microarray was utilized and expression of NIK, IKKα and RelB 
was observed in the tumor cell membrane, cytoplasm and nucleus (Figure 1). Only 
patients with a score for all three proteins were included in the analysis (n=174). 
Expression was divided into quartiles and the median used as the cut-off for low and 
high NIK and IKKα expression, whereas the lower quartile was used for RelB. The 
associations between protein expression and CSS are shown in Table 1. Expression of 
IKKα at any location was not associated with CSS.  However, cytoplasmic NIK was 
significantly associated with poorer CSS (p=0.006, 13.3yrs v 11.3yrs, Figure 2A).  10 
year CSS was stratified from 85% (low) to 68% (high, p=0.005).  Similarly, 
cytoplasmic RelB was significantly associated with poorer CSS (p=0.041, 11.9yrs v 
11.9yrs, Figure 2B).  10 year CSS was stratified from 88% (low) to 73% (high, 
p=0.030). Cytoplasmic NIK and RelB also significantly correlate, suggesting that they 
are both acting as part of the non-canonical pathway (p<0.001, Table 2). Trends 
towards poorer CSS were also seen for membrane NIK (p=0.057, 13.2yrs v 11.3yrs) 
and membrane IKKα (p=0.132, 12.9yrs v 11.6yrs). Again, membrane NIK strongly 
correlates with cytoplasmic NIK (P<0.001) and RelB (p<0.001, Table 2). Similarly, 
membrane IKKα shows associations with cytoplasmic RelB (p=0.084, Table 2). 
Interestingly, nuclear RelB showed a slight trend towards associations with poorer CSS 
(p=0.306, 12.8yrs v 12.2yrs) and strongly correlated with both cytoplasmic NIK and 
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RelB (p<0.001, Table 2).  This suggests that pathway is active in RCC and NIK can 
modulate the pathway to translocate NIK to the nucleus to promote tumorigenesis. 
The relationship between cytoplasmic NIK, RelB and clinicopathological 
characteristics were then examined (Table 2). Cytoplasmic NIK only associated with 
increased CSS (p=0.014).  Whereas cytoplasmic RelB associated with increased grade 
(p=0.020), decreased KM grade (p=0.019) and trended towards associations with 
increased CSS (p=0.079). Cytoplasmic NIK and RelB were then entered into a 
multivariate cox regression survival analysis with stage, grade, and recurrence (Table 
3). Stage (HR 1.63, p=0.047), recurrence (HR 9.75, p<0.001) and cytoplasmic NIK 
(HR 2.85, p=0.009) were independently associated with CSS.   
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DISCUSSION 
This study shows that the non-canonical NF-kappa B pathway is associated with poor 
prognosis in RCC. Specifically, high cytoplasmic NIK and RelB are significantly 
associated with poor CSS, with membrane NIK/IKKα as well as nuclear RelB also 
showing similar trends.  RelB, the most downstream member of the pathway, is 
associated with increased stage and decreased local inflammation, suggesting that the 
non-canonical pathway may downregulate local inflammatory infiltrate to facilitate 
tumor progression.  
These results are similar to other studies that show NIK is a tumorigenic factor. In 
ovarian cancer cells, NIK has been shown to increase cell growth and tumorigenicity.  
In multiple myeloma, it has been proposed tumorigenesis depends upon NIK-driven 
p100/52 activation promoting B-cell survival.11 NIK has also been shown to be a poor 
prognostic factor for glioblastoma.6  Similarly, RelB has also been shown to be a poor 
prognostic factor in many solid tumors.  In non-small cell lung cancer, RelB is 
associated with shorter overall survival, poorer differentiation, tumor invasion, lymph 
node metastasis, distant metastasis and TNM stage.12 In ER+ve breast cancer, RelB and 
p52 were inversely correlated with ER levels and associated with poorer disease-free 
survival.13 In bladder cancer, RelB and p52 levels have been shown to be increased in 
cancer tissue compared to normal bladder. Both RelB and p52 were also shown to be 
correlated with histological grade, stage and lymph node metastasis, suggesting that the 
non-canonical pathway promotes bladder cancer.14  
Little is known about the role of the non-canonical pathway in renal disease including 
RCC. RelB has been shown to play a role in lymphocyte recruitment during acute 
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kidney injury when activated by TWEAK.15 RelB has also been shown to play a role in 
renal ischemia-reperfusion injury (IRI). Silencing of RelB in a mouse model of IRI 
significantly attenuated IRI-induced renal dysfunction, with RelB silenced mice having 
a significant survival advantage.16 However, literature on the effects of the non-
canonical NFκB in RCC is lacking. One study shows that the non-canonical pathway is 
down-regulated in VHL-negative RCC cell lines and this results in diminished 
monocyte cell adhesion17.  However, in this study we show that high expression of 
cytoplasmic NIK and RelB are associated with down regulation of the local 
inflammatory infiltrate and poor prognosis, with cytoplasmic NIK being an 
independent prognostic factor for these patients. Overall, this suggests that non-
canonical pathway may be a potential therapeutic target for RCC.   
To date the inflammatory effects of the NFκB pathway have mainly been attributed to 
the canonical p65/p50 subunit in conjunction with STAT3. However, NIK and RelB 
have previously been shown to be crucial for B-cell development,18 suggesting that the 
non-canonical pathway also plays a role. The study also provides evidence that RelB 
can modulate the local inflammatory infiltrate in RCC patients.   
 
CONCLUSION 
In conclusion, the results of this study indicate that the non-canonical NFκB pathway is 
associated with poorer RCC patient prognosis through NIK and RelB.  The study 
suggests that NIK regulates RelB activation, which in turn down regulates the local 
inflammatory infiltrate to facilitate tumor progression.  Therefore NIK may be a useful 
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prognostic biomarker for this disease and both NIK and RelB may be potential 
therapeutic targets. 
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TITLES AND LEGENDS TO FIGURES 
 
 
Figure 1. Immunohistochemical expression of NIK, IKKα and RelB in RCC 
patients.  Representative images of high membrane, cytoplasmic and nuclear 
expression for NIK, IKKα and RelB. Images are taken from the patient with the highest 
expression of each protein at each location. 
 
Figure 2. The non-canonical Nf-kappa B pathway associates with poorer cancer-
specific survival. (A) Kaplan-Meier curve plotted for cytoplasmic NIK expression 
against cancer-specific survival. (B) Kaplan-Meier curve plotted cytoplasmic RelB 
expression against cancer-specific survival. 
 


TABLES 
 
Table 1.  The relationship between the non-canonical NFκB pathway and cancer-specific 
survival in RCC patients (n=174) 
 
 N (%) 10yr-CSS (SE) P-value 
NIK       Membrane 
 
 
Cytoplasmic 
 
 
Nuclear 
89 (51) 
85 (49) 
 
87 (50) 
87 (50) 
 
87 (50) 
87 (50) 
83 (5) 
70 (6) 
 
85 (5) 
68 (6) 
 
75 (7) 
77 (5) 
0.057 
 
 
0.006 
 
 
0.535 
IKKα     Membrane 
 
 
Cytoplasmic 
 
 
Nuclear 
89 (51) 
85 (49) 
 
87 (50) 
87 (50) 
 
89 (51) 
85 (49) 
80 (6) 
73 (5) 
 
77 (6) 
75 (5) 
 
75 (7) 
76 (5) 
0.132 
 
 
0.502 
 
 
0.209 
RelB      Membrane 
 
 
Cytoplasmic 
 
 
Nuclear 
42 (24) 
132 (76) 
 
48 (27) 
126 (73) 
 
44 (25) 
132 (75) 
79 (8) 
76 (5) 
 
88 (6) 
73 (5) 
 
82 (7) 
75 (5) 
0.821 
 
 
0.041 
 
 
0.306 
%=Percentage, CSS = cancer-specific survival, SE=standard error 
  
Table 2.  Correlations for members of the non-canonical NFB in patients with RCC 
(n=174) 
 
 NIK IKK RelB 
 mem cyto nuc mem cyto nuc mem cyto nuc 
NIK     mem 
cyto 
nuc 
 
 
<0.001 <0.001 
0.075 
0.321 
0.711 
0.116 
0.922 
0.161 
0.227 
0.288 
0.778 
0.043 
<0.001 
0.039 
0.010 
<0.001 
<0.001 
0.025 
0.003 
<0.001 
<0.001 
IKK  mem 
cyto 
nuc 
    
 
<0.001 <0.001 
<0.001 
0.006 
0.154 
0.350 
0.086 
0.120 
0.316 
0.084 
0.722 
0.253 
RelB   mem 
cyto 
nuc 
       <0.001 <0.001 
<0.001 
  
Table 3.  The relationship between clinicopathological characteristics and cytoplasmic 
NIK/RelB expression in RCC patients (n=174) 
 Cytoplasmic NIK Cytoplasmic RelB 
Patients 
Low 
(n=87) 
High 
(n=87) 
P value 
Low 
(n=48) 
High 
(n=126) 
P value 
Age  
≤60 
>60 
 
37 (43) 
50 (57) 
 
47 (54) 
40 (46) 
0.104  
22 (46) 
26 (54) 
 
61 (48) 
65 (52) 
0.664 
Stage  
1 
2 
3 
4 
 
41 (47) 
15 (17) 
29 (34) 
2 (2) 
 
34 (39) 
15 (17) 
33 (38) 
5 (6) 
0.267  
25 (52) 
8 (17) 
14 (29) 
1 (2) 
 
50 (40) 
22 (17) 
48 (38) 
6 (5) 
0.126 
Grade  
I 
II 
III 
IV 
 
8 (9) 
27 (31) 
41 (47) 
11 (13) 
 
4 (5) 
27 (31) 
36 (42) 
19 (22) 
0.161  
6 (13) 
11 (23) 
27 (56) 
4 (8) 
 
7 (6) 
44 (34) 
49 (39) 
26 (21) 
0.020 
Klintrup-Makinen grade 
Strong 
Weak 
 
47 (54) 
40 (46) 
 
40 (46) 
47 (54) 
0.288  
31 (65) 
17 (35) 
 
56 (44) 
70 (56) 
0.019 
Recurrence  
No 
Yes 
 
63 (72) 
24 (28) 
 
66 (76) 
21 (24) 
0.603  
38 (79) 
10 (21) 
 
91 (72) 
35 (28) 
0.357 
Survival  
Alive 
Cancer-specific death 
Non-cancer death 
 
69 (80) 
9 (10) 
9 (10) 
 
54 (62) 
23 (26) 
10 (12) 
0.014  
38 (79) 
4 (8) 
6 (13) 
 
85 (67) 
28 (23) 
13 (10) 
0.079 
 
 
  
Table 4. The relationship between clinicopathological characteristics, the non-canonical 
NF-κB pathway and cancer-specific survival in RCC patients (n=174) 
CI= Confidence intervals 
 Univariate analysis Multivariate analysis 
Patients Hazard ratio 
(95% CI) 
P-value Hazard ratio 
(95% CI) 
P-value 
Clinicopathological Characteristics     
Age (<60/ >60 years) 1.00 (0.50-2.00) 0.991 - - 
Stage (1/2/3/4) 2.29 (1.53-3.44) <0.001 1.63 (1.01-2.63) 0.047 
Grade (I/II/III/IV) 2.15 (1.34-3.44) 0.001 1.28 (0.79-2.07) 0.321 
Klitrup-Makinen Grade (Strong/weak) 0.88 (0.44-1.77) 0.725 - - 
Recurrance (No/Yes) 9.87 (4.43-22.00) <0.001 9.75 (3.85-24.68) <0.001 
Non-canonical NF-kappa B pathway     
Cytoplasmic NIK (low/high) 2.80 (1.29-6.05) 0.009 2.85 (1.30-6.23) 0.009 
Membrane NIK (low/high) 1.28 (0.64-2.58) 0.062 - - 
Cytoplasmic RelB (low/high) 2.85 (1.00-8.13) 0.049 1.24 (0.38-4.04) 0.727 
